Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on European Ledger.
Press releases published on March 2, 2025
Activewear Market Set to Achieve a Valuation of US$ 771.8 billion, Riding on a 6.2% CAGR by 2032
EIN Presswire
·
March 2, 2025
By fabric, the polyester segment led the global activewear market demand and is expected to retain its dominance throughout the forecast period. WILMINGTON, DE, UNITED STATES, March 3, 2025 /EINPresswire.com/ -- The activewear market size was valued at …
Corporate Event Market Size & Share Surpass $723.4 billion 2035, Evolving at a CAGR 6.9% from 2024 to 2035
EIN Presswire
·
March 2, 2025
By platform, the virtual events segment is estimated to witness significant growth, registering a CAGR of 10.8% during the forecast period. WILMINGTON, DE, UNITED STATES, March 2, 2025 /EINPresswire.com/ -- The global corporate event market size was …
Courageous Conservatives PAC Applauds White House for Standing Up to Zelensky
EIN Presswire
·
March 2, 2025
America First Leadership Takes a Stand Against Endless Foreign Entanglements WASHINGTON, DC, UNITED STATES, March 1, 2025 /EINPresswire.com/ -- The Courageous Conservatives Political Action Committee (PAC), an organization dedicated to electing leaders …
How to easily earn USD at home: Cloud mining to easily earn cryptocurrencies
GlobeNewswire
·
March 2, 2025
Monmouthshire, UK, March 02, 2025 (GLOBE NEWSWIRE) -- Alr Miner, a leading AI cloud mining platform, is making waves in the cryptocurrency industry by offering a limited-time $12 login mining bonus to new users. The program is designed to lower the barrier …
Merus annonce les résultats financiers de son quatrième trimestre et de l’ensemble de son exercice 2024, et fait le point sur ses activités
GlobeNewswire
·
March 2, 2025
- Inclusion en cours pour les études d’enregistrement de phase III visant l’évaluation du pétosemtamab en association avec le pembrolizumab en traitement de 1ᵉ ligne pour un CETC r/m PD-L1 et l’évaluation du pétosemtamab en monothérapie de 2ᵉ et 3ᵉ ligne …